about
Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.Rapidly Progressing Myelodysplastic Syndrome Initially Presenting as Acute Leukemia.Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II studyTransfusion-dependent low-risk myelodysplastic patients receiving deferasirox: Long-term follow-up.The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.Mucosal barrier injury, fever and infection in neutropenic patients with cancer: introducing the paradigm febrile mucositis.Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014.The risk of infections in patients with myelodysplastic syndromes in 2016.Reactive oxygen species mediated T lymphocyte abnormalities in an iron-overloaded mouse model and iron-overloaded patients with myelodysplastic syndromes.Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes.Mechanisms of Impaired Neutrophil Migration by MicroRNAs in Myelodysplastic Syndromes.Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen.Monocyte function in patients with myelodysplastic syndrome.Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients.Hypoalbuminemia and hypergammaglobulinemia are associated with an increased infection risk in patients with myeloid malignancies treated with azacitidine. A 3-year monocentric retrospective study.Minimally invasive mitral valve repair via right mini-thoracotomy in patient with myelodysplastic syndrome.Practical Strategies for Management of Lenalidomide-Associated Cytopenias in Myelodysplastic Syndromes With del(5q)
P2860
Q33405470-B24370D2-1504-45A4-BA44-48ED9EA77187Q33565951-CFB26748-4B43-4614-995B-0FDE638B355FQ35050532-1739C225-AD26-4662-A427-B8A3B6B647EBQ37326129-B6580A71-94B0-4C1F-A2B6-CC477F68341CQ38160051-62ACE6EE-6CFA-4AA2-B959-8CDF86604FACQ38196963-4062F9F0-456C-4003-892D-6BEBC380BDA6Q38246766-19E40D78-D79D-4277-8B69-2CDFF100C5A3Q38284455-D08D6845-05D0-44AC-8A82-D17992B8ACBBQ38813702-72CB46BA-A833-4553-84DF-0745FF3E1193Q38831230-E1D98805-0D57-406A-8DB5-65F5568765F9Q39171248-4DDDC097-3E0D-45A7-98B1-8628588C33C0Q40355332-45C4A078-DD68-4127-B1A8-DC31C80D0EF2Q40735979-71906E26-2400-468D-879F-ECF9D7533492Q47125142-75CD5481-F1AE-447C-9CB3-5278BC2F2F2EQ52719307-2C9D6C83-70F2-409C-A52B-7974C94FBECDQ54534916-D85BBE69-EDBF-4054-A2C9-32BD40CA8063Q54753533-EDD2D45C-B4D8-4657-86EA-A8E44DA888C8Q55041005-F9182283-A776-4511-9AC6-3699A68ADCE2Q58585580-6D64F195-0899-4665-A5C3-6FE48BD54872
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Infections in myelodysplastic syndromes
@ast
Infections in myelodysplastic syndromes
@en
Infections in myelodysplastic syndromes
@nl
type
label
Infections in myelodysplastic syndromes
@ast
Infections in myelodysplastic syndromes
@en
Infections in myelodysplastic syndromes
@nl
prefLabel
Infections in myelodysplastic syndromes
@ast
Infections in myelodysplastic syndromes
@en
Infections in myelodysplastic syndromes
@nl
P2093
P2860
P1433
P1476
Infections in myelodysplastic syndromes
@en
P2093
C. Cordonnier
F. Dreyfus
P2860
P304
P356
10.3324/HAEMATOL.2012.063420
P407
P577
2012-10-01T00:00:00Z